PITTSBURGH, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a AI-driven drug discovery company that has expanded its business to include a digital asset strategy focused on ATH, the native
PITTSBURGH, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), an AI-driven drug discovery company that has expanded its business to include a digital asset strategy focused on ATH, the native utility
Appoints Shawn Matthews, CEO of DNA Holdings Venture, Inc., and Former CEO of Cantor Fitzgerald, to its Board of Directors Names Thomas McLaughlin and Sara Turken, JD, as Chief Investment Officer and General Counsel,
Investment creates the world's first Strategic Compute Reserve Strategy complements Predictive Oncology's AI/ML-driven drug discovery and development activities PITTSBURGH, Oct. 08, 2025 (GLOBE NEWSWIRE) --
PITTSBURGH, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug development and discovery, and Every Cure, a leading nonprofit dedicated to identifying and validating
PITTSBURGH, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of
$10 million securities purchase agreement provides efficient and flexible funding in support of strategic multi-million dollar growth initiatives Discussions underway to expand adoption of ChemoFx in the U.S. and
PITTSBURGH, July 08, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery, announced today that it has entered into a standby equity purchase agreement ("SEPA") with YA
PITTSBURGH, June 12, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery, announced today the company has successfully developed 3D organoid models exclusively for
PITTSBURGH, May 27, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery, today issued the following statement regarding its dispute with Renovaro, Inc. Contrary to a
LOS ANGELES, May 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has
LOS ANGELES, May 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has
PITTSBURGH, May 22, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI) moves to leverage its vast biobank of more than 150,000 heterogenous live cell tumor samples and drug response data to aggressively
